These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26382807)

  • 41. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
    Cindolo L; Pirozzi L; Sountoulides P; Fanizza C; Romero M; Castellan P; Antonelli A; Simeone C; Tubaro A; de Nunzio C; Schips L
    BMC Urol; 2015 Sep; 15():96. PubMed ID: 26391357
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Editorial Comment to tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
    Gacci M
    Int J Urol; 2013 Feb; 20(2):202. PubMed ID: 22958135
    [No Abstract]   [Full Text] [Related]  

  • 43. Re: Matthias Oelke, François Giuliano, Vincenzo Mirone, Lei Xu, David Cox, Lars Viktrup. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61:917-25.
    Goyal NK; Goel A; Yadav R
    Eur Urol; 2012 Aug; 62(2):e39; author reply e40. PubMed ID: 22633359
    [No Abstract]   [Full Text] [Related]  

  • 44. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Re: Reasons for prescription change of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2015 Apr; 193(4):1317. PubMed ID: 25890537
    [No Abstract]   [Full Text] [Related]  

  • 47. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
    Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
    Urology; 2016 May; 91():154-7. PubMed ID: 26826590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Zhu LL; Feng ZJ; Zhou Q
    Clin Interv Aging; 2015; 10():621-2. PubMed ID: 25848238
    [No Abstract]   [Full Text] [Related]  

  • 49. Current pharmacological treatment options for male lower urinary tract symptoms.
    Strittmatter F; Gratzke C; Stief CG; Hedlund P
    Expert Opin Pharmacother; 2013 Jun; 14(8):1043-54. PubMed ID: 23641819
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Editorial comment to Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
    Akino H
    Int J Urol; 2014 Jul; 21(7):676. PubMed ID: 24588836
    [No Abstract]   [Full Text] [Related]  

  • 51. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
    World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Re: Hartmut Porst, Edward D. Kim, Adolfo R. Casabé, et al., for the LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-13.
    Serefoglu EC; Mitchell GC; Hellstrom WJ
    Eur Urol; 2012 May; 61(5):e45-6; author reply e47-8. PubMed ID: 22342774
    [No Abstract]   [Full Text] [Related]  

  • 54. What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study.
    Matsukawa Y; Kato M; Funahashi Y; Majima T; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2017 Sep; 36(7):1809-1815. PubMed ID: 28102554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments.
    Welliver C; Essa A
    Urol Clin North Am; 2016 Aug; 43(3):393-404. PubMed ID: 27476132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Re: Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.
    Kaplan SA
    J Urol; 2015 Mar; 193(3):948. PubMed ID: 25765413
    [No Abstract]   [Full Text] [Related]  

  • 57. Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Masumori N
    Int J Urol; 2015 Jun; 22(6):589. PubMed ID: 25827235
    [No Abstract]   [Full Text] [Related]  

  • 58. Editorial Comment from Dr Oh-oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Oh-Oka H
    Int J Urol; 2015 Jun; 22(6):588. PubMed ID: 25827197
    [No Abstract]   [Full Text] [Related]  

  • 59. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Editorial comment to "Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin".
    Fujimura T
    Int J Urol; 2014 Jan; 21(1):113. PubMed ID: 23662925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.